Hinge Health Inc. Class A Common Stock vs Nano Dimension Ltd - ADR — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Nano Dimension Ltd - ADR trades at $1.39 (market cap $306.41M). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 27.7× Nano Dimension Ltd - ADR's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| HNGE | NNDM | |
|---|---|---|
Market Cap | $8.48B | $306.41M |
Volume | 879,799 | 1,735,346 |
Sector | Health | Technology |
52-Week High | $105.14 | $2.14 |
52-Week Low | $31.17 | $1.21 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $8.10B | -$98.44M |
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Nano Dimension (NNDM) trades at $1.41, down 6.62% with a bearish technical signal. The company shows revenue growth to $102.44M in 2025 but deepens net losses to -$293.30M, resulting in a negative net margin of -286.32%. Recent strategic moves include appointing a new board member and cost-saving initiatives targeting $25M in annual cash burn reduction. The stock faces significant selling pressure with 18 sell signals versus 7 buy signals in technical indicators.
The outlook remains challenging with persistent losses despite revenue growth. Investment opportunity exists in the company's cash position of $757.96M and low EV/EBITDA of 0.19, but risks include negative cash flow, leadership transitions, and shareholder activism. The stock trades near support levels with institutional sentiment cautious amid ongoing restructuring efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →